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Purpose: To evaluate the effect of agalsidase beta on longitudinal health-
related quality of life in patients with Fabry disease.Methods: The SF-36
Health Survey was used to measure health-related quality of life in Fabry
Registry patients. Seventy-one men and 59 women who were treated with
agalsidase beta (median dose: 1.0 mg/kg/2 weeks) and who had baseline
and at least 2 yearly posttreatment health-related quality of life measure-
ments were included in these analyses. A repeated measures model was
used to analyze change in score from baseline. Results: Men improved in
the physical component summary and in all eight scales of the SF-36 after
1 and 2 years and in the mental component summary after 1 year of
agalsidase beta treatment (P  0.05). Women improved in the mental
component summary and in six of the eight scales after 1 and/or 2 years of
treatment. Patients whose baseline SF-36 scores were below the median
showed the greatest improvements. These responses were comparable with or
greater than the published effects of various treatments for multiple sclerosis,
rheumatoid arthritis, central neuropathic pain, and Gaucher disease. Conclu-
sion:Long-term treatment with agalsidase beta resulted in substantial improve-
ments in health-related quality of life in bothmen andwomen; the effect was
more pronounced in men. Genet Med 2010:12(11):703–712.
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Fabry disease is a rare X-linked metabolic disorder caused byinsufficient activity of the lysosomal enzyme -galactosi-
dase A. As a result, glycolipids with terminal -galactosidic
linkages, particularly globotriaosylceramide, accumulate in var-
ious tissues and cell types.1 The progressive accumulation of
glycolipids eventually impairs critical organ function. The early
symptoms of Fabry disease, including neuropathic pain in the
extremities (acroparesthesia), hypohidrosis, and gastrointestinal
discomfort typically begin during childhood.2–4 Some patients
experience severe episodes of neuropathic pain (Fabry pain
crises); these episodes can last for a day or more and may occur
every few weeks or months. Later in life, many patients develop
life-threatening disease manifestations, including chronic renal
disease, cardiovascular disease, and strokes.5–9 Patients with
Fabry disease, particularly men, have a substantially reduced
life expectancy.10 Clinical depression is common in patients
with Fabry disease, and the probability that patients with Fabry
disease suffer from depression is strongly correlated with the
degree that symptoms interfere with their everyday lives.11
Compared with the general US population, patients with un-
treated Fabry disease, particularly women, exhibit substantially
reduced health-related quality of life (HRQL) with increasing
age.8,12–14
Enzyme replacement therapy (ERT) with agalsidase beta
(recombinant human -galactosidase A) clears globotriaosylce-
ramide from vascular endothelial cells of various tissues.15,16
Long-term agalsidase beta treatment also stabilizes renal func-
tion17,18 and cardiac function.19 However, there is little infor-
mation on the effects of ERT on patients’ self-reported HRQL,
in terms of physical, mental, and social well-being.17,20,21 The
purpose of the current analyses was to evaluate the effect of
agalsidase beta on HRQL outcomes in Fabry Registry patients,




The Fabry Registry is an ongoing, observational database
that compiles clinical and investigative data on an international
cohort of patients with Fabry disease. As of June 5, 2009, the
Fabry Registry had enrolled 3182 patients, including 1587 men
and 1592 women. All patients with Fabry disease are eligible to
enroll in the Fabry Registry, regardless of age, gender, symp-
toms, or whether they are receiving ERT. Patient and physician
participation is voluntary. Patients provide informed consent
through local institutional review boards/Ethics Committees
and may decline to participate or withdraw consent at any time.
SF-36 data were collected from Fabry Registry patients aged
14 years and older. The Fabry Registry recommends that par-
ticipating physicians collect SF-36 data from their patients at
the time of enrollment and every 6 months thereafter.22 Fabry
Registry patients included in these analyses were required to
From the 1Department of Endocrinology, National University Hospital, Copen-
hagen, Denmark; 2Department of Neurology, San Bassano Hospital, Bassano
del Grappa; 3Department of Neuroscience, Universita` degli Studi di Padova,
Padua, Italy; 4Department of Medicine, University of Wu¨rzburg, Wu¨rzburg,
Germany; 5Department of Pediatrics, Division of Clinical Genetics, Columbia
University College of Physicians and Surgeons, New York City, New York;
6Division of Human Genetics, Cincinnati Children’s Hospital, Cincinnati, Ohio;
7Inatos do Metabolismo–CREIM, Universidade Federal de Sa˜o Paulo, Sa˜o
Paulo, Brazil; 8Department of Neurology, Massachusetts General Hospital,
Boston; and 9Department of Biomedical Data Sciences and Informatics, Gen-
zyme Corporation, Cambridge, Massachusetts.
Ulla Feldt-Rasmussen, MD, PhD, DMSc, National University Hospital,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: ufeldt@rh.dk.
Disclosure: The Fabry Registry is sponsored by Genzyme Corporation.
U.F.-R., K.S., R.J.H., M.B., A.M., and A.P.B. serve on the Genzyme-
sponsored Fabry Registry Boards of Advisors. D.B.-J. and F.O.B. are full-
time employees of Genzyme Corporation. T.W. has received unrestricted
grants from Genzyme for other research projects.
Submitted for publication March 30, 2010.
Accepted for publication June 19, 2010.
Published online ahead of print September 29, 2010.
DOI: 10.1097/GIM.0b013e3181f13a4a
ARTICLE
Genetics IN Medicine • Volume 12, Number 11, November 2010 703
have a baseline SF-36 assessment within 12 months before
initiating agalsidase beta treatment. Men were required to have
at least 3 yearly posttreatment SF-36 assessments (i.e., 0 to12
months, 12 to 24 months, and 24 to 36 months). Too few
women had 3 years of posttreatment SF-36 assessments avail-
able to perform meaningful statistical analyses at that time
point; therefore, women were required to have at least 2 yearly
posttreatment SF-36 assessments (0 to 12 months and 12 to
24 months).
Outcome measure
The SF-36 Health Survey is a validated instrument that has
been extensively used to evaluate HRQL in patients with vari-
ous chronic diseases and in the general population.23,24 The
SF-36 includes eight scales that relate to various self-reported
aspects of physical, mental, and social well-being and function,
and two summary measures: the physical component summary
(PCS) score and mental component summary (MCS) score. The
eight scales and the characteristics they measure include Phys-
ical Functioning, limitations in performing various physical
activities; Role Physical, impact of physical health on comple-
tion of work or other daily activities; Bodily Pain, pain magni-
tude and its effect on daily activities; General Health, overall
health perception; Vitality, perceived energy levels; Social
Functioning, impact of physical and mental health on the ability
to engage in normal social activities; Role Emotional, impact of
emotional health on work or other daily activities; and Mental
Health, self-reported mood levels.24 The scores for all scales are
on a 100-point scale, with a higher score indicating better
HRQL. In the general adult US population, average SF-36
scores range from 64 to 87 in men (N  1055) and from 58 to
82 in women (N  1412).23 Seven points has been reported to
represent a clinically meaningful improvement in HRQL.25 For
the Vitality subscale specifically, five points has been reported
to represent a clinically meaningful improvement in groups with
Vitality scores below average,26 as do patients with Fabry
disease.8
Clinical events
The long-term progression of Fabry disease is associated
with chronic renal disease, cardiovascular disease, and cerebro-
vascular events. Renal events were defined as chronic renal
dialysis (40 days) or renal transplantation. Cerebrovascular
events were defined as strokes. Cardiovascular events were
defined as any arrhythmia (including atrial and ventricular),
myocardial infarction, congestive heart failure, angina pectoris,
or invasive cardiac interventions (e.g., pacemaker placement,
coronary bypass, percutaneous coronary intervention valve re-
placement, and transplantation).
Statistical analyses
The effect of agalsidase beta treatment on HRQL was eval-
uated for each gender by calculating changes in score from
baseline to the various time points for each of the eight SF-36
scales in a repeated measures model using SAS statistical soft-
ware 9.1 (SAS Institute Inc., Cary, NC). Age at baseline was
included as a covariate in the repeated measure models for the
analyses of all patients but not for the analyses of patients
subgrouped by age or by baseline SF-36 scores. Differences
were considered to be statistically significant if P  0.05 in the
repeated measures analyses. To further evaluate the effect of
age at initiation of treatment, patients were subgrouped into
younger and older categories, within each gender, based on the
median ages at the time treatment was started. The effect of
baseline disease severity, in terms of impaired HRQL, was
evaluated by subgroup analyses of patients with SF-36 scores
below median for each scale, within each gender. Changes in
SF-36 scores observed in agalsidase-beta treated patients were
also qualitatively compared with changes in SF-36 scores re-
ported in patients treated for other clinical disorders resembling
Fabry disease.
RESULTS
As of June 5, 2009, 71 men in the Fabry Registry had SF-36
assessments reported at baseline and at least three posttreatment
assessments during a period of 36 months. At that time, 59
women had SF-36 assessments reported at baseline and at least
two posttreatment assessments during a period of 24 months.
The 36-month data that were available for women (N  28)
generally resembled the 24-month data from the cohort of 59
women, across the various scales (data not shown). The 71 men
had received agalsidase beta for an average period of 81  31
months (mean  standard deviation) at 1.0  0.14 mg/kg every
other week, as an averaged dose during the period of SF-36 data
collection. The 59 women had received agalsidase beta for an
average period of 41  22 months (mean  standard deviation)
at 0.9  0.22 mg/kg every other week, as an averaged dose
during the period of SF-36 data collection.
Although the Fabry Registry recommends collecting SF-36
data every 6 months,22 a relatively small percentage of patients
had longitudinal SF-36 data reported. The possibility that these
analyses were susceptible to selection bias was evaluated by
comparing the agalsidase beta-treated men and women included
in these analyses with other agalsidase beta-treated men and
women in the Fabry Registry (i.e., those for whom the necessary
SF-36 assessments were not reported). These two groups of
patients were compared separately within each gender by ana-
lyzing various demographic and clinical characteristics, as sum-
marized in Table 1. The 71 men included in the HRQL analyses
were diagnosed at a younger age than 898 other agalsidase
beta-treated men in the Fabry Registry (24 vs. 30 years) and
began treatment at a younger age (mean: 33 vs. 37 years).
Compared with the 898 other agalsidase beta-treated men in the
Fabry Registry, the 71 men included in the HRQL analyses had
fewer renal events and fewer strokes before they initiated agal-
sidase beta treatment, as shown in Table 1. Among women, the
only significant difference found between the two patient
groups was that a higher proportion of the 59 women included
in these analyses were from Europe (58%), compared with
the 404 other agalsidase beta-treated women in the Fabry
Registry (40%).
As shown in Table 2, men reported significantly higher PCS
and MCS scores after 0 to12 months of treatment. PCS scores
were also significantly higher in men after 12 to 24 months of
treatment. In women, MCS scores were significantly improved
after 0 to 12 months and 12 to 24 months of agalsidase
beta treatment. There was a trend toward higher PCS scores
in women after treatment, but there may have been too few
women in this cohort for the trend to reach statistical signif-
icance (N  59).
As shown in Figure 1 (Panel A), men reported significantly
higher scores in all eight scales of the SF-36 after 0 to 12
months and 12 to 24 months of agalsidase beta treatment.
Men reported the greatest improvements in the Role Physical
(9–15 points) and Role Emotional scales (6–11 points). After
24 to 36 months of treatment, significant improvements were
observed in six of the eight scales (all except Social Functioning
and Role Emotional). Mens’ mean scores were slightly lower
during the third year of treatment, compared with the first and
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second years, across all scales. However, there were no statis-
tically significant differences between any of the scales at the 24
to36-month time point versus the 0 to12-month time point.
Physical Functioning and Vitality scores were significantly
lower at the 24 to 36-month time point compared with the 12
to 24-month time point, although mean scores remained sig-
nificantly higher than pretreatment levels at that time.
Mean SF-36 scale scores for women are shown in Figure 1
(Panel B). Women reported significantly higher scores in six of
the eight scales after 0 to12 months and/or 12 to24 months
of agalsidase beta treatment (all except Physical Functioning
and Role Emotional). Women reported the greatest improve-
ments in the Role Physical (10 points) and General Health
scales (9 points) after 0 to 12 months of treatment and in
Social Functioning (10 points) after 12 to 24 months of
treatment.
The influence of age at initiation of treatment on the effect of
agalsidase beta treatment on HRQL is shown in Figure 2. Men
who were older than the median age at the time they initiated
treatment (33 years or older) reported substantial improvements
in all scale scores at two or more time points (Panel A). These
men reported the greatest improvements in the Role Physical
(14–15 points) and the Role Emotional scales (20–22 points).
The younger group of men reported significant gains in only the
Role Physical and Bodily Pain scales (data not shown). Com-
Table 2 Effect of agalsidase beta treatment on HRQL as
measured by SF-36 PCS and MCS scores
Men (N  71),
mean  SEM




Baseline 38.8  1.29 36.8  1.53
0–12 mo 42.1  1.19a 38.4  1.50
12–24 mo 43.0  1.30a 38.5  1.48
24–36 mo 41.3  1.29 —
Mental component
summary scores
Baseline 46.0  1.22 45.9  1.41
0–12 mo 48.9  1.08a 49.2  1.26a
12–24 mo 48.4  1.20b 48.8  1.36a
24–36 mo 47.3  1.22 —
aP  0.05 by repeated measures model using age at baseline as a covariate.
bP  0.0614.
SEM, standard error of the mean.
Table 1 Demographic and clinical characteristics of Fabry Registry patients treated with agalsidase beta
Men in HRQL cohort
(N  71)
Other Fabry Registry men
(N  898)
Women in HRQL cohort
(N  59)
Other Fabry Registry women
(N  404)
Age at Fabry diagnosisa (yr)
n 70 888 58 398
Mean (SD) 24 (13.9)b 30 (15.1) 41 (13.8) 37 (16.0)
Median (min, max) 20.5 (0–65) 30 (0–79) 42 (11–69) 37 (0–70)
Age at initiation of agalsidase
beta treatment (yr)
Mean (SD) 33 (11.5)b 37 (13.0) 46 (12.2) 44 (13.4)
Median (min, max) 33 (16–66) 37 (14–80) 48 (16–71) 46 (14, 76)
Age at last follow-up (yr)
Mean (SD) 40 (11.1) 41 (13.2) 50 (11.9) 47 (13.7)
Median (min, max) 40 (23–71) 41 (14–82) 52 (20–72) 48 (15–78)
Geographic region, n (%)
Europe 31 (44) 394 (43) 34 (58)c 161 (40)
The United States 30 (42) 340 (38) 17 (29) 190 (47)
Rest of world 10 (14) 164 (18) 8 (14) 53 (13)
Clinical eventsd before initiation
of agalsidase beta
treatment, n (%)
19 (27) 333 (37) 19 (32) 123 (30)
Renal events, n (%) 5 (7)c 150 (17) 0 18 (5)
Cardiovascular events, n (%) 16 (23) 213 (24) 15 (25) 89 (22)
Strokes, n (%) 1 (1)c 79 (9) 5 (9) 33 (8)
aAge at diagnosis was calculated based on the number of patients for whom diagnosis dates were available, as indicated.
bP  0.05 by t test.
cP  0.05 by 2 test (compared with other Fabry Registry patients of the same gender).
dAs defined in section “Materials and Methods.”
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Fig. 1. Effect of agalsidase beta treatment on SF-36 scores in Fabry Registry men and women. Data are expressed as
average SF-36 scores at baseline (open bars), after 0–12 months of treatment (light gray bars), 12–24 months of
treatment (dark gray bars), and (for men only) 24–36 months of treatment (black bars). Error bars represent the upper
limit of 95% confidence intervals. Panel A: average SF-36 scores amongN 71 men. Panel B: average SF-36 scores among
N  59 women. *P  0.05; significantly different from baseline value by repeated measures model, using age at baseline
as a covariate.
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Fig. 2. Effect of agalsidase beta treatment on SF-36 scores among Fabry Registry patients older than median age at
initiation of treatment. Data are expressed as average SF-36 scores at baseline (open bars), after 0–12 months of treatment
(light gray bars), 12–24 months of treatment (dark gray bars), and (for men only) 24–36 months of treatment (black
bars). Error bars represent the upper limit of 95% confidence intervals. Panel A: average SF-36 scores among N  35 men
aged 33 years or older at the time agalsidase beta treatment was initiated. Panel B: average SF-36 scores among N  30
women aged 48 years or older at the time agalsidase beta treatment was initiated. *P  0.05; significantly different from
baseline value by repeated measures model.
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Fig. 3. Effect of agalsidase beta treatment on SF-36 scores among Fabry Registry patients with baseline scores below the
median. Data are expressed as average SF-36 scores at baseline (open bars), after 0–12 months of treatment (light gray
bars), 12–24 months of treatment (dark gray bars), and (for men only) 24–36 months of treatment (black bars). Error bars
represent the upper limit of 95% confidence intervals. Panel A: average SF-36 scores among men with baseline scores less
than the median. Panel B: average SF-36 scores among women with baseline scores below the median. The numbers of
patients who had baseline scores less than the median are indicated below each scale on the x-axis. Different numbers of
patients had scores below the median at baseline for each scale because some patients had baseline scores equal to the
median for particular scales. *P  0.05; significantly different from baseline value by repeated measures model.
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pared with men who were younger than 33 years when they
initiated treatment, the older men had significantly lower base-
line SF-36 scores in the Physical Functioning and Role Emo-
tional scales. The mean Physical Functioning score was 60 in
older men versus 75 in younger men (P  0.008), and the mean
Role Emotional score was 51 in older men versus 80 in younger
men (P  0.002). Mean scores in the General Health, Vitality,
Social Functioning, and Mental Health scales also tended to be
lower in older men, but these differences (ranging from 8 to 11
points) did not achieve statistical significance (P values 0.05–
0.10). In contrast, age at initiation of treatment was not a major
factor in womens’ overall response to agalsidase beta treatment,
in terms of SF-36 scores. Women who were older than the
median age at the time they initiated treatment (48 years or
older) reported statistically significant gains in two scales: 15
points in Role Physical and 10–11 points in Social Functioning.
Women who were younger than 48 years when they initiated
treatment also reported significant gains in two scales: 10 points
in Bodily Pain and 11 points in General Health (data not
shown). Unlike in men, there were no consistent differences in
baseline SF-36 scores between the older and younger groups of
women (data not shown).
The effect of agalsidase beta treatment on HRQL in the
subgroup of patients whose baseline scale scores were less than
the median score of the overall cohort is shown in Figure 3. As
shown in Panel A, men with baseline scores below the median
reported large improvements in all eight SF-36 scales after 12,
24, and 36 months of treatment. These patients reported the
greatest improvements in the Role Physical (30–50 points) and
Role Emotional scales (30–39 points). Similar results were
reported by women whose baseline scores were less than the
median score for each scale (Panel B). These women reported
statistically significant improvements in all scales after up to 12
months and 24 months of agalsidase beta treatment. The great-
est improvements of women reported were in the Role Physical
(24–25 points), Social Functioning (21–23 points), and Role
Emotional Scales (33–38 points).
Pain, a common symptom of Fabry disease, is an important
part of HRQL, and these analyses indicate that Bodily Pain
improves after treatment in both men and women. Beyond the
SF-36, the Fabry Registry also asks physicians to indicate on
case report forms whether their patients reported pain, the
frequency of such pain, and what, if any, medications were used
to treat pain. Unfortunately, only a subset of the patients in this
cohort had this type of data recorded before the initiation of
agalsidase beta treatment (20/71 men, 28% and 38/59 women,
64%). The limited data available were insufficient to determine
whether meaningful changes in the reported frequency of pain
or in the use of pain medications occurred after treatment (data
not shown).
The magnitude of improvement in HRQL of patients with
Fabry disease after agalsidase beta treatment is shown in com-
parison with various treatments for other chronic diseases in
Table 3. The upper half of Table 3 shows average baseline
(pretreatment) SF-36 scale scores for Fabry Registry patients
and scores previously reported for patients with rheumatoid
arthritis,27 multiple sclerosis,28 central neuropathic pain,29 and
Gaucher disease.30
Across most scales, Fabry Registry patients reported baseline
SF-36 scores that were generally similar to those of patients
with multiple sclerosis28 and patients with Gaucher disease.30
However, in terms of baseline General Health and Vitality scale
scores, patients with Fabry disease had lower scores, more
closely resembling patients with rheumatoid arthritis27 and cen-
tral neuropathic pain.29 The lower half of Table 3 shows mean
change from baseline in response to treatment with agalsidase
beta (patients with Fabry disease), abatacept (patients with
rheumatoid arthritis), natalizumab (patients with multiple scle-
rosis), pregabalin (patients with central neuropathic pain), and
imiglucerase (patients with Gaucher disease). Across nearly all
scales, the changes from baseline in response to agalsidase beta
treatment reported by Fabry Registry men were substantially
larger than the change from baseline in patients with rheumatoid
arthritis treated with abatacept, in patients with multiple scle-
rosis treated with natalizumab, and patients with central neuro-
pathic pain treated with pregabalin. There were two exceptions:
the Mental Health scale improved by 4.6 points in response to
agalsidase beta treatment in Fabry men, which was the same as
the response to abatacept in rheumatoid arthritis; also, the
Bodily Pain scale improved by 14.6 points in response to
agalsidase beta treatment in Fabry men versus 15.6 points in
response to patients with central neuropathic pain treated with
pregabalin. The posttreatment improvements in Fabry mens’
HRQL most closely resembled that of patients with Gaucher
disease treated with imiglucerase for 24 months (Table 3).
DISCUSSION
These analyses were undertaken to evaluate the effect of
agalsidase beta on HRQL. For this purpose, repeated measures
analyses were used to evaluate longitudinal SF-36 data from
130 Fabry Registry patients who were treated with agalsidase
beta for a minimum of 2 years.
In men, HRQL was improved after the first 2 years of
treatment with agalsidase beta in all eight SF-36 scales and the
PCS score. The greatest improvements were reported in the
scales that measure the impact of physical and mental health on
the ability to perform work and daily activities, i.e., the Role
Physical and Role Emotional scales, respectively; these are core
aspects of HRQL. The magnitude of these improvements in
SF-36 scores is consistent with what has been reported to be
clinically important.25,26,31 Men reported sustained improve-
ments during the third year of treatment, except for the Social
Functioning and Role Emotional scales. Mean SF-36 scores in
men tended to be lower during the third year of treatment
compared with the first year, although there was no statistically
significant difference. Although a true decline in HRQL at
longer follow-up periods cannot be excluded, it could be spec-
ulated that this tendency toward lower scores during the third
year may reflect a “response shift,” where patients’ expectations
are set at a higher level after an initial good response.32 Alter-
natively, this may represent a “ceiling effect,” i.e., after initial
improvements during the first year, further changes may be
more difficult to appreciate. In addition, the SF-36 questionnaire
asks about patients’ well-being “in the last 4 weeks” and not
“since baseline.”
Women reported statistically significant improvements in six
of the eight scales during the first 2 years of agalsidase beta
treatment (all except Physical Functioning and Role Emotional)
and the MCS score. The greatest improvements reported by
women were in the Role Physical and General Health scales.
The summary component scores (e.g., PCS and MCS) sug-
gest that men tended to experience more improvement in phys-
ical aspects of HRQL, whereas women tended to experience
more improvement in mental or psychosocial aspects of HRQL.
Overall, men experienced greater improvements in HRQL in
response to agalsidase beta treatment, compared with women.
This is probably related to the fact that men generally experi-
ence more severe manifestations of this X-linked disorder1,8
and, therefore, have more room for improvement in response to
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treatment. Indeed, when patients were grouped according to
baseline SF-36 scores, those with baseline scores less than the
median exhibited much larger improvements in HRQL, among
both genders. However, this latter finding could also reflect a
methodological ceiling effect; that is, patients with scores in the
higher range (i.e., “better” scores) have less room for improve-
ment because of the fact that the scale stops at 100. In this
population, 55% of women (34/59) and 61% of men (43/71)
reported a maximum score in one or more of the eight scales
(data not shown).
Age at initiation of treatment was an important factor in men
but not in women. Men who were aged 33 years or older (the
median age at which agalsidase beta treatment was initiated)
when they began receiving treatment showed greater improve-
ments in SF-36 scores and improved in more scales than did
men who were younger than 33 years when treatment was
initiated. The older group of men also had lower SF-36 scores
in all eight scales at baseline. As described earlier, this provided
more room to improve in the 100-point scale, when compared
with younger men. However, women aged 48 years or older (the
median age at which agalsidase beta treatment was initiated in
women) had statistically significant responses in the same num-
ber of subscales as did younger women. Unlike in men, older
women did not have lower baseline SF-36 scores, when com-
pared with the younger group.
The magnitude of these improvements in HRQL was put into
some perspective by comparing these changes with those re-
ported by patients undergoing treatment for other chronic dis-
eases. In previous studies, HRQL in untreated men with Fabry
disease has been reported to be similar to that of patients
undergoing renal dialysis and patients affected with acquired
immune deficiency syndrome.12 HRQL in untreated women
with Fabry disease has been reported to be similar to that of
patients with rheumatoid arthritis or multiple sclerosis.14 The
improvement in HRQL reported by patients with Fabry disease
in response to agalsidase beta treatment is substantial; after
12–24 months, men reported average improvements of 9 or
more points in five of the eight 100-point scales. Much smaller
improvements were reported by patients with rheumatoid ar-
thritis who were treated with abatacept,27 patients with multiple
sclerosis who were treated with natalizumab,28 and patients with
central neuropathic pain who were treated with pregabalin.29 In
particular, patients with Fabry disease reported substantially
greater improvements in the Physical Functioning and Role
Physical scales after agalsidase beta treatment, compared with
the effects of natalizumab in patients with multiple sclerosis or
Table 3 Comparison of effects of various treatments on health-related quality of life in other chronic diseases
Fabry disease






















Physical functioning 67.5 (2.72) 59.0 (3.32) 26.2 70.2 31.5 73.6
Role physical 45.1 (4.87) 44.6 (5.51) 30.5 55.0 12.5 62.5
Bodily pain 57.0 (3.08) 54.0 (3.34) 30.6 73.0 30.7 68.3
General health 43.6 (2.48) 43.9 (3.00) 34.9 53.7 46.2 65.7
Vitality 43.5 (2.84) 39.6 (3.15) 35.1 48.3 45.8 47.0
Social functioning 68.8 (3.00) 64.0 (3.74) 33.0 71.4 51.3 73.4
Role emotional 65.3 (4.59) 63.8 (5.63) 35.7 66.9 60.0 71.9




Physical functioning 9.1 (2.31)b 2.4 (2.66) 5.3b 1.2b 2.5 9.0b
Role physical 14.6 (5.16)b 6.1 (5.84) 6.7b 6.8b 0 20.0b
Bodily pain 9.6 (2.75)b 6.1 (3.02)b 8.7b 1.0 15.6b 9.6b
General health 6.2 (2.40)b 4.5 (2.40) 3.9b 3.8b 3.7 6.3
Vitality 9.3 (2.29)b 7.3 (3.18)b 6.9b 3.7b 4.5 14.6b
Social functioning 5.1 (2.59)b 8.4 (3.04)b 7.4b 4.0b 12.5 14.5b
Role emotional 10.3 (5.03)b 4.0 (5.80) 6.3b 6.8b 5.0 18.1b
Mental health 4.6 (2.13)b 5.1 (2.30)b 4.6b 2.4b 2.8 5.0
aFabry Registry data are stratified by gender because Fabry disease is an X-linked disorder, and men are generally more severely affected. Data in parentheses represent
standard error of the mean.
For agalsidase beta data, bP  0.05 by repeated measures models with adjustment for age at initiation of agalsidase beta treatment. For abatacept data, bP  0.01 by
analysis of variance.27 For natalizumab data, bP  0.05 by analysis of covariance corrected for differences in baseline scores.28 For pregabalin data, bP  0.01 by analysis
of covariance corrected for differences in baseline scores.29 For imiglucerase data, bP  0.05 by Wilcoxon signed-rank test.30
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pregabalin in patients with central neuropathic pain. This is
relevant because patients with Fabry disease frequently experi-
ence chronic fatigue, as do patients with multiple sclerosis or
neuropathic pain. Among the four diseases that were compared
with Fabry disease, the overall improvement in the HRQL of
Fabry men in response to agalsidase beta most closely resem-
bled that of patients with type 1 Gaucher disease who were
treated with imiglucerase.30 Although type 1 Gaucher disease
affects a different set of organ systems than Fabry disease
(primarily liver, spleen, and bone marrow), it is also a lysosomal
storage disorder that is associated with chronic pain and long-
term disability.33 Nevertheless, these comparisons are associ-
ated with certain caveats. Rheumatoid arthritis and multiple
sclerosis most commonly affect women, whereas the most se-
verely affected patients with Fabry disease are men. In addition,
not all patients with neuropathic pain respond to pregabalin, and
a relatively small number of patients (N  32) were included in
the study of imiglucerase treatment on Gaucher disease,30
which, similar to Fabry disease, is a very rare disorder.
There are several limitations that must be considered when
interpreting these analyses. The findings are limited by the
voluntary and observational nature of data reported to registries.
The Fabry Registry recommends that physicians ask patients
who receive agalsidase beta treatment to complete the SF-36
health survey on enrollment, at baseline (i.e., immediately be-
fore initiation of treatment), and at 6-month intervals thereafter.
However, not all patients visit their physicians at the recom-
mended intervals, and treating physicians determine the actual
frequency at which the various assessments are administered.
Relatively, few patients who have been treated with agalsidase
beta have reported SF-36 assessments at each recommended
time point. Compared with other agalsidase beta-treated men in
the Fabry Registry, 71 men who met the criteria to be included
in the HRQL cohort were diagnosed at a younger age, initiated
treatment at a younger age, and had experienced fewer serious
clinical events at the time they began treatment. This suggests
that these men were not in a more advanced state of disease
progression than other men in the Fabry Registry at the time
they began agalsidase beta treatment. There were no significant
differences in these parameters between the 59 women included
in the HRQL cohort compared with other agalsidase beta-
treated women in the Fabry Registry.
The second limitation to consider is that the SF-36 measures
relatively generic aspects of HRQL. Generally, generic instru-
ments are less sensitive to changes compared with specific
instruments, and there are likely to be certain aspects of HRQL
that affect patients with Fabry disease but are not measured by
the SF-36. For example, it has previously been shown that 62%
of men with Fabry disease experienced impact on their sex
life34; an aspect not measured by the SF-36. The same study
reported that 70% experienced interference with their job and
62% were limited in social activities, which is consistent with
the findings from the current analyses.
Perhaps, the most important limitation of these findings is the
lack of a parallel control group. It is difficult to identify un-
treated Fabry Registry patients to serve as an appropriate com-
parator group for this population. Patients with Fabry disease
who receive treatment are generally more severely affected by
Fabry disease than those who have not been treated. In addition,
HRQL declines with age in untreated patients with Fabry dis-
ease, particularly women.8 Therefore, untreated patients must
be matched by age and gender with treated patients. At this
point, there are too few agalsidase beta-treated patients in the
Fabry Registry who have appropriate longitudinal SF-36 data to
subgroup patients in this manner and perform meaningful sta-
tistical analyses. For this reason, the effect of agalsidase beta
treatment on HRQL was expressed as average change from
baseline, such that each patient’s baseline data served as his or
her own pretreatment control.
Another important issue is that pain and quality of life are
subjective experiences that can be strongly influenced by patients’
expectations.32,35 A Phase 3 randomized double-blinded placebo-
controlled study showed that agalsidase beta was a safe and effec-
tive treatment for Fabry disease.15 After 20 weeks of treatment,
patients treated with agalsidase beta exhibited significant clearance
of globotriaosylceramide from the microvascular endothelium of
various tissues, whereas placebo-treated patients did not.15 How-
ever, both the agalsidase beta-treated and the placebo-treated pa-
tients reported significant decreases in pain and significant im-
provements in the Role Physical component of the SF-36 after 20
weeks,15 which made it impossible to differentiate treatment-re-
lated effects on pain and HRQL from a placebo effect. These
patients were followed in a long-term extension study in which all
patients received agalsidase beta for up to 54 months.17 Renal
function remained stable after 54 months of treatment, and signif-
icant improvements in the Physical Functioning, Body Pain, and
Role Emotional SF-36 scales were also reported at that time.17 The
improvements in HRQL reported after these longer durations of
treatment (54 months in the Phase 3 extension study and 24–36
months in the current Fabry Registry analyses) may be more likely
to be treatment-related effects of agalsidase beta than the improve-
ments reported after the initial 20 weeks of the Phase 3 study.15
In conclusion, our analyses indicate that long-term treatment
with agalsidase beta is associated with substantially improved
HRQL in both men and women with Fabry disease; the effect is
more pronounced in men. In men, largest improvements were in
the impact of physical and mental health on performance of
work and daily activities. Women also reported the largest
improvements in the impact of physical health not only on
performance but on general health perception and social func-
tion. Lower HRQL before beginning treatment was associated
with greater improvement in response to agalsidase beta, as was
older age among men, but not women. All patients with Fabry
disease should be monitored closely and appropriately treated
for pain and other symptoms that limit their everyday activities.
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